Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks

  1. Arrabal-Durán, P.
  2. Rodríguez-González, C.G.
  3. Chamorro-de-Vega, E.
  4. Gijón-Vidaurreta, P.
  5. Herranz-Alonso, A.
  6. Sanjurjo-Sáez, M.
Aldizkaria:
International Journal of Clinical Practice

ISSN: 1742-1241,  1368-5031

Argitalpen urtea: 2017

Alea: 71

Zenbakia: 8

Mota: Artikulua

DOI: 10.1111/IJCP.12968 GOOGLE SCHOLAR
Datuen iturria: Scopus